CN Patent

CN119101680A — 多核苷酸、药物组合物及其用途

Assigned to Liangzhu Laboratory · Expires 2024-12-10 · 1y expired

What this patent protects

本申请公开了一种多核苷酸、药物组合物及其用途。本申请中，新设计了多种靶向核纤层蛋白A突变体mRNA的3'非翻译区的多核苷酸序列，能够在Lamin AmRNA阶段降低核纤层蛋白A突变体(例如早老蛋白)的表达水平，同时不影响Lamin C的正常转录，因此毒副作用更低，作为预防或治疗与核纤层蛋白A突变相关疾病(尤其是早老症)方面前景广阔。

USPTO Abstract

本申请公开了一种多核苷酸、药物组合物及其用途。本申请中，新设计了多种靶向核纤层蛋白A突变体mRNA的3'非翻译区的多核苷酸序列，能够在Lamin AmRNA阶段降低核纤层蛋白A突变体(例如早老蛋白)的表达水平，同时不影响Lamin C的正常转录，因此毒副作用更低，作为预防或治疗与核纤层蛋白A突变相关疾病(尤其是早老症)方面前景广阔。

Drugs covered by this patent

Patent Metadata

Patent number
CN119101680A
Jurisdiction
CN
Classification
—
Expires
2024-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Liangzhu Laboratory
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.